Topical ciclosporin in the treatment of ocular surface disorders

S. Tatlipinar, Esen Karamursel Akpek

Research output: Contribution to journalReview articlepeer-review


Mounting evidence suggests that inflammation is the key factor in the pathogenesis of various ocular surface diseases, with a complex interplay of genetic, environmental, and psychosocial factors. Management of these conditions is often challenging. Topical corticosteroids, with their associated side effects, are the mainstay of current treatments for patients with vision threatening disease. Ciclosporin A is an immunomodulator that specifically inhibits T lymphocyte proliferation. Recently, a topical ciclosporin preparation was approved by the US Food and Drug Administration and became available for use in ophthalmology. Given the increasing use of ciclosporin eye drops, the goal of this article is to provide the reader with an overview of the well established uses of ciclosporin and to help refine the questions that should be addressed by future investigations.

Original languageEnglish (US)
Pages (from-to)1363-1367
Number of pages5
JournalBritish Journal of Ophthalmology
Issue number10
StatePublished - Oct 2005

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Topical ciclosporin in the treatment of ocular surface disorders'. Together they form a unique fingerprint.

Cite this